摘要
Abstract
Objective To investigate the efficacy of sugemalimab combined with cisplatin plus paclitaxel regimen in patients with advanced non-small cell lung cancer(NSCLC).Methods Seventy patients with advanced NSCLC were selected as study objects;by using a randomized single-blind method,they were assigned into a control group and a sugemalimab group,with 35 cases in each group.The control group received cisplatin plus paclitaxel therapy,while the sugemalimab group adopted sugemalimab in addition to the control group's regimen.The short-term efficacy,occurrence of adverse reactions,prognosis,levels of cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen,squamous cell carcinoma antigen(SCC-Ag),carbohydrate antigen 125(CA125)and carbohydrate antigen 50(CA50),and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30(EORTCQLQ-C30)scores were compared between the two groups before and after treatment.Results After three treatment cycles,the sugemalimab group showed a significantly higher disease control rate compared to the control group[80.00％(28/35)vs.57.14％(20/35),P＜0.05];the levels of CYFRA21-1,carcinoembryonic antigen,SCC-Ag,CA125,and CA50 were all significantly lower in the sugemalimab group than those in the control group(all P＜0.01).The sugemalimab group also exhibited significantly lower EORTCQLQ-C30 symptom scores compared to the control group,with significantly higher functional and overall quality of life scores(all P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).After one year of follow-up,the survival rate was significantly higher in the sugemalimab group than that in the control group[73.53％(25/34)vs.51.52％(17/33),P＜0.05].Conclusion Combining sugemalimab with the cisplatin plus paclitaxel regimen improves treatment efficacy in patients with advanced NSCLC,further reduces tumor marker levels,increases quality of life and survival rates,and demonstrates a favorable safety.关键词
舒格利单抗/顺铂/紫杉醇/晚期/非小细胞肺癌Key words
sugemalimab/cisplatin/paclitaxel/advanced stage/non-small cell lung cancer分类
医药卫生
